| Filed On | Filing |
|---|---|
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Connecting Innovation to Purpose Corporate Presentation October 15, 2026 Exhibit 99.1 |
| 30 Sep 2026 | SCHEDULE 13G |
| 15 Sep 2026 |
Form 4: Ben Yong, Director
Sold 2,000 shares ($15.7K) |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity |
| 17 Aug 2026 |
Form 4: Nicacio Leonardo Viana, Chief Medical Officer
Received 58,333 shares as a grant or award · Granted 191,676 Stock options (right to buy) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 |
Form 4: Saxena Nishant C, Chief Business Officer
Bought 2,600 shares ($25K) |
| 10 Aug 2026 |
Form 4: Cohen Yuval, Director
Sold 17,000 shares ($171K) |
| 10 Aug 2026 |
Form 4: Moran Sean F., Chief Financial Officer
Sold 12,000 shares ($121K) |
| 07 Aug 2026 | 424B5 |
| 07 Aug 2026 | 144 |
| 07 Aug 2026 | 144 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 04 Aug 2026 |
Form 3: Nicacio Leonardo Viana, Chief Medical Officer
No securities owned |
| 27 Jul 2026 | SCHEDULE 13G |
| 27 Jul 2026 | 144 |
| 06 Jul 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 17 Jun 2026 | S-8 |
| 11 Jun 2026 |
Form 4: Kung Winston, Director
Sold 2,026 shares ($16K) |
Loading...
